Next generation sequencing has greatly enhanced our capability to identify mutations associated with myeloid malignancies. However, accurate and timely detection of complex variants can be challenging.
Microsatellite Instability: how do microsatellites mutations correlate with cancer?
Learn about the technology behind the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution from the lead developer, Dr. Christian Pozzorini.
By leveraging expertly curated evidence, powered by JAX-CKB, and SOPHiA GENETICS’ patented algorithms through the SOPHiA DDM platform, users can then use OncoPortal™ Plus to accurately identify clinical associations and actionable biomarker profiles.
Learn about the impact of HRD on cancer development, how HRD status may predict sensitivity to certain treatments, and the different HRD testing methods available.
The President acknowledged that the US still has much further to come in advancing data-driven initiatives and that many Americans sadly do not realize the struggle of seeking answers during the cancer diagnostic journey until it’s too late.
About half of all breast cancer patients develop the disease outside of the period of ages 50-69 and could greatly benefit from earlier detection. Today, we know that age alone is not enough to accurately estimate breast cancer risk.
The medical research community has been buried in data since well before the global COVID-19 pandemic. How they’re now managing the extreme additional influx of SARS-CoV-2 data determines the outcomes of a lab’s overall research capabilities.
You never know when life is going to throw you a curve ball. You can plan for something to happen down to the dotted line, but a simple phone call can change your whole perspective on life.
More than six people die every hour in the US from a blood cancer. Solutions can’t come fast enough for those who suffer with these cancers all around the world.
Newsletter updates for April 2021
Newsletter updates for February 2021
